--- title: "InflaRx (IFRX) news: offering" url: "https://aibio.space/companies/inflarx-n-v/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IFRX offering news: InflaRx prices $150,000,000 share offering at $2.00 and closes it a day later. InflaRx N.V. (NASDAQ: IFRX), Germany." --- IFRX InflaRx N.V. NASDAQ · Germany # InflaRx (IFRX) news IFRX offering news Financings · 2026-08-14 ## [InflaRx registers up to $65,000,000 more in shares for sales program](https://aibio.space/news/inflarx-registers-up-65-000-000-more-shares-sales-program/) Sales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds. ## Latest InflaRx news 1. 2026-05-06 Financings [InflaRx prices $150,000,000 share offering at $2.00 and closes it a day later](https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/) InflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026. 2. 2026-04-28 Listings [InflaRx regains Nasdaq bid price compliance](https://aibio.space/news/inflarx-regains-nasdaq-bid-price-compliance/) Nasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed. ## InflaRx at a glance - **Ticker**: IFRX - **Listing**: NASDAQ - **Country**: Germany ### Related companies - [Bio-Gate](https://aibio.space/companies/bio-gate/) XETR: BIG - [BioNTech](https://aibio.space/companies/biontech/) NASDAQ: BNTX - [TME Pharma](https://aibio.space/companies/tme-pharma-n-v/) EURONEXT: ALTME - [Novogenia](https://aibio.space/companies/novogenia/) XETR: 7V0 - [FamiCord](https://aibio.space/companies/famicord/) XETR: V3V - [BRAIN Biotech](https://aibio.space/companies/brain-biotech/) XETR: BNN - [Heidelberg Pharma](https://aibio.space/companies/heidelberg-pharma/) XETR: HPHA - [Bayer](https://aibio.space/companies/bayer/) XETR: BAYN ### Also on NASDAQ - [CG Oncology](https://aibio.space/companies/cg-oncology/) CGON - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Spectral AI](https://aibio.space/companies/spectral-ai/) MDAI - [Canopy Growth](https://aibio.space/companies/canopy-growth/) CGC - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) HALO ## Questions about InflaRx Has InflaRx raised money recently? Our latest story on this, dated May 6, 2026: "InflaRx prices $150,000,000 share offering at $2.00 and closes it a day later". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/). What is the ticker symbol of InflaRx? InflaRx N.V. trades under the ticker IFRX on NASDAQ. Where is InflaRx listed? InflaRx N.V. is listed on NASDAQ. Our directory also records these other listings: GETTEX:IF0; LS:A2H7A5; LSX:A2H7A5. What is the SEC CIK of InflaRx? The SEC Central Index Key (CIK) for InflaRx N.V. is 1708688. Its filings are on SEC EDGAR. How many shares does InflaRx have outstanding? 72,292,859 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-20. Which country or territory is InflaRx listed under? Our directory records InflaRx N.V. under Germany. What does InflaRx do? Our directory classifies InflaRx N.V. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of InflaRx? The ISIN recorded for InflaRx N.V. is NL0012661870. Does aibio.space cover InflaRx? aibio.space lists InflaRx N.V. among 2,820 public biotech companies and publishes its news here as stories appear. Where is InflaRx incorporated? SEC records list its state or country of incorporation as P7. What is the latest InflaRx (IFRX) stock news? Our latest story on InflaRx, dated Aug 14, 2026: "InflaRx registers up to $65,000,000 more in shares for sales program". Sales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds. [Source](https://aibio.space/news/inflarx-registers-up-65-000-000-more-shares-sales-program/). How long will InflaRx's cash last? From our story of May 6, 2026: The company says that, with the proceeds of this offering, it has "a projected cash runway through 2029." It names proof-of-concept readouts in aHUS, IgAN and C3G and a Phase 2 readout in AAV as the milestones that runway is meant to reach. [Source](https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/). Is InflaRx at risk of delisting? Our latest listing story, dated Apr 28, 2026: "InflaRx regains Nasdaq bid price compliance". Nasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed. [Source](https://aibio.space/news/inflarx-regains-nasdaq-bid-price-compliance/). Is InflaRx a smaller reporting company? SEC records list InflaRx N.V.'s filer category as: Non-accelerated filer. Where is InflaRx headquartered? SEC records list its business address as WINZERLAER STR. 2, JENA, Germany, 07745. ## Investor discussion: InflaRx Members talk about InflaRx (IFRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at InflaRx, newest first. Each line links the filing it comes from. 1. 2026-08-14 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036126033149/ny20075001x3_424b5.htm) 2. 2026-05-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019288/ny20072539x1_424b5.htm) 3. 2026-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036126017448/ef20071644_ex99-1.htm) 4. 2026-03-20 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000121390026032065/ea0281674-20f_inflarx.htm) 5. 2026-03-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036126009438/ef20067722_ex99-1.htm) 6. 2025-09-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036125034839/ef20055418_ex99-1.htm) 7. 2025-07-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036125025788/ef20051933_ex99-1.htm) 8. 2025-03-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm) 9. 2025-02-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708688/000114036125004369/ny20043420x1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IFRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-IFRX/). ## SEC filings and registration - **SEC name**: InflaRx N.V. - **CIK**: 1708688 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IFRX (Nasdaq) - **State or country of incorporation**: P7 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: WINZERLAER STR. 2, JENA, Germany, 07745 - **Phone**: 49 3641 508180 - **Shares outstanding**: 72,292,859 as of 2025-12-31 (20-F filed 2026-03-20) - **Former names**: Fireman B.V. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1708688/000114036126040509/ef20084212_6k.htm) filed 2026-10-22 - [424B5](https://www.sec.gov/Archives/edgar/data/1708688/000114036126033149/ny20075001x3_424b5.htm) filed 2026-08-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_6k.htm) filed 2026-08-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1708688/000114036126026933/ef20077063_6k.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019534/ef20072665_6k.htm) filed 2026-05-07 - [424B5](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019440/ny20072539x2_424b5.htm) filed 2026-05-07 - [424B5](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019288/ny20072539x1_424b5.htm) filed 2026-05-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1708688/000114036126019215/ef20072565_6k.htm) filed 2026-05-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001708688), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details InflaRx N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IFRX, recorded under Germany. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: InflaRx N.V. - **Ticker**: IFRX - **Listing**: NASDAQ - **Country or territory**: Germany - **Business scope**: Biotechnology - **ISIN**: NL0012661870 - **Other listed symbols**: GETTEX:IF0; LS:A2H7A5; LSX:A2H7A5 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IFRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/inflarx-n-v/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "InflaRx (IFRX) news: offering", 2026-10-31, https://aibio.space/companies/inflarx-n-v/